Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Proinflammatory mediators and genetic background in oncogene mediated tumor progression.

Russell JP, Engiles JB, Rothstein JL.

J Immunol. 2004 Apr 1;172(7):4059-67.

2.

Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression.

Pufnock JS, Rothstein JL.

J Immunol. 2009 May 1;182(9):5498-506. doi: 10.4049/jimmunol.0801284.

3.

Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors.

Russell JP, Shinohara S, Melillo RM, Castellone MD, Santoro M, Rothstein JL.

Oncogene. 2003 Jul 17;22(29):4569-77.

PMID:
12881713
4.

Human papilloma virus 16 E7 oncogene does not cooperate with RET/PTC 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice.

Portella G, Borselli C, Santoro M, Gerbasio D, D'Armiento MR, Dumont JE, Ledent C, Rothstein JL, Vecchio G, Fusco A.

Oncol Res. 2001;12(8):347-54.

PMID:
11589306
5.

The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium.

Russell JP, Powell DJ, Cunnane M, Greco A, Portella G, Santoro M, Fusco A, Rothstein JL.

Oncogene. 2000 Nov 23;19(50):5729-35.

6.

A thyroid tumor-specific antigen formed by the fusion of two self proteins.

Powell DJ Jr, Eisenlohr LC, Rothstein JL.

J Immunol. 2003 Jan 15;170(2):861-9.

7.

The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation.

Buckwalter TL, Venkateswaran A, Lavender M, La Perle KM, Cho JY, Robinson ML, Jhiang SM.

Oncogene. 2002 Nov 21;21(53):8166-72.

8.
9.

Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene.

Portella G, Salvatore D, Botti G, Cerrato A, Zhang L, Mineo A, Chiappetta G, Santelli G, Pozzi L, Vecchio G, Fusco A, Santoro M.

Oncogene. 1996 Nov 7;13(9):2021-6.

PMID:
8934550
10.

Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers.

Burniat A, Jin L, Detours V, Driessens N, Goffard JC, Santoro M, Rothstein J, Dumont JE, Miot F, Corvilain B.

Endocrinology. 2008 Oct;149(10):5107-17. doi: 10.1210/en.2008-0531. Epub 2008 Jun 26.

PMID:
18583418
11.

Impact of connexin32 deletion on E7 or RET/PTC3 oncogene-driven growth and neoplastic transformation of the thyroid gland.

Prost G, Bernier-Valentin F, Croset M, Rousset B.

Endocr Relat Cancer. 2009 Sep;16(3):873-84. doi: 10.1677/ERC-09-0091. Epub 2009 Jun 9.

12.

Molecular events in follicular thyroid tumors.

Kroll TG.

Cancer Treat Res. 2004;122:85-105. Review.

PMID:
16209039
13.

Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice.

Cho JY, Sagartz JE, Capen CC, Mazzaferri EL, Jhiang SM.

Oncogene. 1999 Jun 17;18(24):3659-65.

14.

Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations.

Ali HM, Urbinati G, Chapuis H, Desmaele D, Bertrand JR, Couvreur P, Massaad-Massade L.

PLoS One. 2014 Apr 23;9(4):e95964. doi: 10.1371/journal.pone.0095964. eCollection 2014.

15.

A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.

Ngan ES, Lang BH, Liu T, Shum CK, So MT, Lau DK, Leon TY, Cherny SS, Tsai SY, Lo CY, Khoo US, Tam PK, Garcia-Barceló MM.

J Natl Cancer Inst. 2009 Feb 4;101(3):162-75. doi: 10.1093/jnci/djn471. Epub 2009 Jan 27.

PMID:
19176457
16.

RET/PTC fusion gene products in patients suffering from thyroid carcinomas.

Bachrati CZ, Pocsai G, Raskó I.

Laryngoscope. 1999 Jun;109(6):1011-5. No abstract available.

PMID:
10369300
17.

The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation.

Tian F, Grimaldo S, Fujita M, Cutts J, Vujanovic NL, Li LY.

J Immunol. 2007 Sep 15;179(6):3742-51. Erratum in: J Immunol. 2007 Nov 1;179(9):6369. Fugita, Mitsugu [corrected to Fujita, Mitsugu].

18.

Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein.

Nabarro S, Himoudi N, Papanastasiou A, Gilmour K, Gibson S, Sebire N, Thrasher A, Blundell MP, Hubank M, Canderan G, Anderson J.

J Exp Med. 2005 Nov 21;202(10):1399-410. Epub 2005 Nov 14.

19.

Genetic mutations in thyroid carcinoma.

Taccaliti A, Boscaro M.

Minerva Endocrinol. 2009 Mar;34(1):11-28. Review.

PMID:
19209125
20.

The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK.

Neely RJ, Brose MS, Gray CM, McCorkell KA, Leibowitz JM, Ma C, Rothstein JL, May MJ.

Oncogene. 2011 Jan 6;30(1):87-96. doi: 10.1038/onc.2010.396. Epub 2010 Sep 6.

Supplemental Content

Support Center